A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients

Exclusion Criteria9

• Diagnosed as other active depigmentation disease.
• At screening or baseline visits, subject exhibits active inflammatory dermatologic disease or symptoms that in the opinion of investigators would interfere of vitiligo evaluation or response to treatment.
• Uncontrolled thyroid function at screening as determined by the investigator.
• Use of permanent depigmentation treatment or skin grafts.
• Use of phototherapy, topical or systemic treatments within certain time frame prior to Day1.
• Have active bacterial/virus/other pathogens infection or infestation that require medical intervention.
• Have progressive or uncontrolled systemic disease, or other concomitant chronic disease that the investigators believe unsuitable to participate the study.
• History of alcohol and drug abuse within one year prior to screening; History of neurological or mental disorders with diagnosis records, such as severe depression, suicidal tendencies, epilepsy, dementia, etc.
• Have any other reasons determined by the investigator that the subject is not eligible for the study.